Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 6/20 | 0.36 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716432 | 0.80 | ESR2 (0.52) | — | |
| SCHEMBL8990276 | 0.79 | SIGMAR1 (0.46) | TSHRHCRTR1HCRTR2KDM1AMAOB | |
| SCHEMBL5856089 | 0.78 | HCRTR1 (0.43) | HCRTR1HCRTR2POLBKDM1ARCOR1 | |
| SCHEMBL1305947 | 0.77 | HCRTR2 (0.42) | TSHRHSD17B10HCRTR1HCRTR2TAAR1 | |
| SCHEMBL17476831 | 0.77 | HCRTR2 (0.42) | TSHRHSD17B10HCRTR1HCRTR2TAAR1 | |
| SCHEMBL1305945 | 0.77 | HCRTR2 (0.42) | TSHRHSD17B10HCRTR1HCRTR2TAAR1 | |
| SCHEMBL12987346 | 0.76 | KDM1A (0.43) | BRD4TAAR1KDM1ARCOR1KCNH2 | |
| SCHEMBL5858111 | 0.73 | TMEM97 (0.36) | HCRTR1HCRTR2TAAR1POLB | |
| SCHEMBL1502602 | 0.73 | CHRNB2 (0.31) | POLB | |
| SCHEMBL31339233 | 0.71 | MAPT (0.43) | TSHRBRD4HSD17B10POLBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | TSHR 1666/4885BRD4 2415/4885HSD17B10 35/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | TSHR 2487/4885BRD4 2253/4885HSD17B10 37/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | TSHR 2672/4885BRD4 2369/4885HSD17B10 39/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | TSHR 2672/4885BRD4 2369/4885HSD17B10 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.